Latin American consensus on guidelines for chronic migraine treatment

Giacomozzi, Alex Rodrigo Espinoza; Vindas, Alexander Parajeles; Silva, Ariovaldo Alberto da; Bordini, Carlos Alberto; Buonanotte, Carlos Federico; Roesler, Célia Aparecida de Paula; Brito, Cláudio Manoel; Pérez, Cristina Tejera; Carvalho, Diana Paula de Souza Rêgo Pinto; Macedo, Djacir Dantas Pereira de; Piovesan, Élcio Juliato; Sarmento, Elder Machado; Melhado, Eliana Meire; Dach, Fabíola; Kowacs, Fernando; Sobrino, Fidel; Rabello, Getúlio Daré; Rada, Grisel; Souza, Jano Alves de; Casanovas, Juana Rosa; Durán, Juan Carlos; Calia, Leandro Cotoni; Medina, Luis Roberto Partida; Queiroz, Luiz Paulo; Ciciarelli, Marcelo Cedrinho; Valênça, Marcelo Moraes; Cusicanqui, Maria; Jimenez, Maria Karina Velez; Goycochea, Maria Tereza; Peres, Mário Fernando Prieto; Sandoval, Mario Victor Fuentealba; Vincent, Maurice; Gomes, Michel Volcy; Díez, Mónica Terán; Aranaga, Nayeska; Barrientos, Nelson; Kowacs, Pedro André; Filho, Pedro Ferreira Moreira

doi:10.1590/0004-282x20130066

Cited by 25 publications

(44 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with chronic migraine are more likely suffering from be divorced, be unemployed psychological comorbidity, and high risk with acute medication overuse for headache treatment (Bigal et al, ; Silberstein et al, ; Tepper et al, ). The expert opinion suggests that patients with chronic migraine should receive abortive and preventive treatments (Giacomozzi et al, ; Irimia, Carmona‐Abellan, & Martinez‐Vila, ; Lionetto et al, ; Pringsheim et al, ; Puledda, Messina, & Goadsby, ). But there are few treatments for preventing chronic migraine.…”

Section: Introductionmentioning

confidence: 99%

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis

Han

Liu²,

Xiong

et al. 2019

Brain and Behavior

View full text Add to dashboard Cite

Background CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic migraine. Methods Database including Cochrane Library and PubMed were systematically searched for randomized controlled trials (RCTs) which are about CGRP mAb in preventing treatment of chronic migraine. Evaluating the bias and quality of RCTs was carried out according to the Cochrane collaboration's tool for assessing risk of bias. The data analysis was carried out by reviewer manager 5.2. Results Totally, 6 articles enrolled in the present meta‐analysis, including 4 independent clinical trials and 3,166 patients. After pooled analysis, it indicated that CGRP mAb improved 50% responder rate (OR = 2.42, 95% CI = [2.04, 2.87], I 2 = 0%, p < 0.00001) and 75% responder rate (OR = 1.95, 95% CI = [1.30, 2.91], I 2 = 0%, p = 0.001), as compared with placebo. And there was no difference in incidence of adverse events between CGRP mAb group and placebo group except incidence of injection site discomfort. Conclusions CGRP mAb is an effective and safety preventive treatment for chronic migraine.

show abstract

Section: Introductionmentioning

confidence: 99%

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis

Han

Liu²,

Xiong

et al. 2019

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…The European Federation of Neurological Societies (EFNS) has no dedicated CM guidelines either, but in the migraine treatment guidelines from 2009, topiramate is the only medication mentioned as having evidence for CM . Additionally, in the 2013 Latin American consensus on guidelines for CM treatment, there are again recommendations for both onabotulinumtoxinA and topiramate with level A evidence …”

Section: Discussionmentioning

confidence: 99%

Chronic Migraine – Evolution of the Concept and Clinical Implications

Medrea

Christi

2018

Headache

View full text Add to dashboard Cite

Chronic migraine is a relatively newly recognized disease. We have an increasing number of medications studied specifically in chronic migraines, and these are briefly introduced. Additionally, there are guidelines to help design trials in chronic migraine. A valid future research question is to further study the efficacy of the medications studied in an undifferentiated migraine population, as there is economic pressure to use these medications as first line.

show abstract

“…We will mention a few other Brazilians and the IHS member under whose supervision they studied or worked with: Luiz Paulo Queiroz/Alan M. Rapoport; Fernando Kowacs/Peter Goadsby; Mario Peres/Stephen Silberstein. Marcelo Eduardo Bigal started his training in headache medicine under the supervision of José Geraldo Speciali and Carlos Bordini, finalizing both MSc and PhD theses at Ribeirao Preto School of Medicine‐USP, and receiving postdoctoral training with Richard B. Lipton in New York.…”

Section: International Relationshipmentioning

confidence: 99%

“…In Rio de Janeiro, São Paulo, Paraná, Santa Catarina, and Rio Grande do Sul, there are several centers dealing with headache disorders and an excellent scientific production has been made by a number of headache specialists, mentioning Abouch Krymchantowski, Carla da Cunha Jevoux, Maurice Vincent, Pedro Ferreira Moreira Filho, Jano Alves de Souza, Maria Eduarda Nobre in Rio de Janeiro; Celia P. Roesler, Deusvenir de Souza Carvalho, Eliova Zukerman, Mario Fernando Prieto Peres,…”

Section: Publications In Headache Medicinementioning

confidence: 99%

“…129 We will mention a few other Brazilians and the IHS member under whose supervision they studied or worked with: Luiz Paulo Queiroz/Alan M. Rapoport; Fer-nando Kowacs/Peter Goadsby; Mario Peres/Stephen Silberstein. Marcelo Eduardo Bigal started his training in headache medicine under the supervision of José Geraldo Speciali 52,53, and Carlos Bordini,52,53,89,90,92,168,169,[171][172][173][180][181][182][183][184][185]…”

Section: International Relationshipmentioning

confidence: 99%

See 1 more Smart Citation

Headache Research and Medical Practice in Brazil: An Historical Overview

2015

Self Cite

View full text Add to dashboard Cite

Since the creation of the Brazilian Headache Society in 1978, substantial developments have taken place in both research and clinical practice in the field of headache medicine in Brazil. The Society now has almost 300 members throughout the country, actively working to improve the health of the general population and, in particular, diagnose and treat headache disorders. In addition, in a few large cities, such as São Paulo, Rio de Janeiro, Recife, Ribeirão Preto, Curitiba, and Porto Alegre, headache specialists have come together to promote research projects and increase knowledge in the field through MSc, PhD, and postdoctoral programs. Furthermore, scientific journals have emerged and books have been published to record and disseminate Brazilian scientific production in headache medicine. In this narrative review, we will briefly describe some important aspects of headache medicine in Brazil from prehistoric times to the present day, discuss the origin of headache medicine as a specialty in Brazil, the principal publications dealing with headache disorders, the use of plants and other unconventional forms of treatment used by faith healers, the main training centers, and the research produced to date by Brazilians. In conclusion, in recent years enormous progress has been made in headache medicine in Brazil stimulating us to review and expand our role in an increasingly international scenario.

show abstract

Latin American consensus on guidelines for chronic migraine treatment

Cited by 25 publications

References 93 publications

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis

Chronic Migraine – Evolution of the Concept and Clinical Implications

Headache Research and Medical Practice in Brazil: An Historical Overview

Contact Info

Product

Resources

About